Michael Benkowitz, President and COO of United Therapeutics (UTHR), has demonstrated a consistent pattern of selling activity in the company’s stock over recent months, with no recorded purchases. Since January 2026, Benkowitz has executed 11 sales totaling over $27.5 million, with transactions occurring nearly every week. Notable sales include a $7.03 million disposal on February 17, 2026, and a $6.9 million sale on January 26, 2026, alongside smaller but repeated dispositions in the $3.7–$4.4 million range. The transactions also included stock awards (coded "M"), such as a $1.72 million grant on February 2, 2026, though these were not market purchases.
Benkowitz’s trading history reveals a long-term net selling bias, with $275.3 million in total sales against $77.1 million in buys across 284 filings—all tied to UTHR. The recent activity suggests an acceleration, with multi-million-dollar sales occurring in tight succession. While the sales could represent routine portfolio management, their frequency and scale indicate a deliberate reduction in exposure. The absence of buys during this period further underscores a one-directional trend, though the retained stock awards suggest ongoing equity-based compensation. United Therapeutics remains Benkowitz’s sole reported holding, with no diversification into other securities.
AI-assisted summary